Turnstone Biologics Corp. - Common Stock, par value $0.001 per share (TSBX)

Q: What does CUSIP 90042W100 represent in this 13F holders report?

CUSIP 90042W100 is the security identifier for TSBX - Turnstone Biologics Corp. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held TSBX - Turnstone Biologics Corp. - Common Stock, par value $0.001 per share in Q2 2025?

23 institutional investors reported TSBX - Turnstone Biologics Corp. - Common Stock, par value $0.001 per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 90042W100

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 23,142,592
Total 13F shares: 8,434,667
Share change: -1,958,428
Total reported value: $3,026,098
Price per share: $0.36
Number of holders: 23
Value change: -$754,416
Number of buys: 7
Number of sells: 11

Quarterly Holders Quick Answers

What is CUSIP 90042W100?
CUSIP 90042W100 identifies TSBX - Turnstone Biologics Corp. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025
Previous quarter: Q1 2025

Recent filing periods for CUSIP 90042W100:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of TSBX - Turnstone Biologics Corp. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13F	Company	13%	3,099,265	$1,270,699	—	31 Mar 2025	13F
FMR LLC	13F 13D/G 3/4/5	Company · Other*	4.9% from 13D/G	1,133,987	$464,935	—	31 Mar 2025	13F 13D/G 3/4/5
BML Capital Management, LLC	13F	Company	4.8%	1,103,386	$452,388	—	31 Mar 2025	13F
PFM Health Sciences, LP	13F	Company	4%	932,348	$382,263	—	31 Mar 2025	13F
TAKEDA PHARMACEUTICAL CO LTD	13F	Company	3.9%	895,824	$367,288	—	31 Mar 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	3.9%	891,531	$365,528	—	31 Mar 2025	13F
Point72 Asset Management, L.P.	13F	Company	3.8%	878,933	$360,363	—	31 Mar 2025	13F
72 Investment Holdings, LLC	13F	Company	2.4%	549,980	$225,492	—	31 Mar 2025	13F
VANGUARD GROUP INC	13F	Company	2.2%	515,087	$211,186	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.59%	136,780	$56,088	—	31 Mar 2025	13F
BlackRock, Inc.	13F	Company	0.18%	42,400	$17,384	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.17%	40,200	$16,482	—	31 Mar 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.17%	38,858	$15,932	—	31 Mar 2025	13F
XTX Topco Ltd	13F	Company	0.15%	35,741	$14,654	—	31 Mar 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.11%	25,305	$10,375	—	31 Mar 2025	13F
Nordwand Advisors, LLC	13F	Company	0.09%	20,000	$8,200	—	31 Mar 2025	13F
NORTHERN TRUST CORP	13F	Company	0.08%	18,405	$7,546	—	31 Mar 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	0.08%	17,833	$6,000	—	31 Mar 2025	13F
HRT FINANCIAL LP	13F	Company	0.05%	12,083	$4,000	—	31 Mar 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.02%	4,761	$1,952	—	31 Mar 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	196	$81	—	31 Mar 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	121	$50	—	31 Mar 2025	13F
UBS Group AG	13F	Company	0%	71	$29	—	31 Mar 2025	13F
Sammy J. Farah	3/4/5	President & CEO, Director	— class O/S missing	155,321	—	—	16 Oct 2023	3/4/5
Saryah Azmat	3/4/5	Chief Business Officer	— class O/S missing	56,637	—	—	16 Oct 2023	3/4/5
Venkat Ramanan	3/4/5	Chief Financial Officer	— class O/S missing	46,606	—	—	16 Oct 2023	3/4/5
Stewart Abbot	3/4/5	Chief Scientific Officer	— class O/S missing	45,542	—	—	16 Oct 2023	3/4/5
P. Joseph Campisi Jr.	3/4/5	Chief Legal Officer	— class O/S missing	44,377	—	—	16 Oct 2023	3/4/5
Kanya Rajangam	3/4/5	Director	— class O/S missing	12,770	—	—	03 Jun 2024	3/4/5
Robert J. Gould	3/4/5	Director	— class O/S missing	12,770	—	—	03 Jun 2024	3/4/5
William D. Waddill	3/4/5	Director	— class O/S missing	12,770	—	—	03 Jun 2024	3/4/5
Michael F. Burgess	3/4/5	Interim Chief Medical Officer, Director	— class O/S missing	11,464	—	—	16 Oct 2023	3/4/5

Institutional Holders of Turnstone Biologics Corp. - Common Stock, par value $0.001 per share (TSBX) as of Q2 2025

As of 30 Jun 2025, Turnstone Biologics Corp. - Common Stock, par value $0.001 per share (TSBX) was held by 23 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 8,434,667 shares. The largest 10 holders included ORBIMED ADVISORS LLC, FMR LLC, BML Capital Management, LLC, TAKEDA PHARMACEUTICAL CO LTD, Point72 Asset Management, L.P., 72 Investment Holdings, LLC, CITADEL ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, DELTEC ASSET MANAGEMENT LLC, and VANGUARD GROUP INC. This page lists 23 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q1 2025 Across Filers

Q1 2025 holders

Q2 2025 holders

Holder diff

Investor	Q1 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q1 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.